BioMarin Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 1/6
BioMarin Pharmaceutical heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 10.5%, terwijl de Biotechs-industrie de winst zag groeien met 33.8% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 13%. Het rendement op eigen vermogen van BioMarin Pharmaceutical is 4.3%, en het heeft een nettomarge van 8.3%.
Belangrijke informatie
10.51%
Groei van de winst
8.83%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.04% |
| Inkomstengroei | 13.02% |
| Rendement op eigen vermogen | 4.33% |
| Nettomarge | 8.29% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • May 14
BMRN: Pending Amicus Acquisition Will Recast Earnings Power Despite Treatment Franchise Uncertainty
Analysts have nudged their fair value estimate for BioMarin Pharmaceutical to $89.96, reflecting updated assumptions on discount rate, revenue growth, profit margins, and a higher future P/E following a mix of recent price target increases and reductions across the Street. Analyst Commentary Street research on BioMarin Pharmaceutical has been active, with a mix of higher and lower price targets and one recent coverage reinstatement at Goldman Sachs.Seeking Alpha • May 06
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
Summary BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026. The BMN 401 and BMN 333 programs, alongside PALYNZIQ label expansion, further diversify BMRN's growth opportunities and de-risk the investment thesis. Read the full article on Seeking Alpha
Narratiefupdate • Apr 29
BMRN: Fair Value View Weighs Voxzogo Headwinds Against Amicus Acquisition Potential
Analysts have trimmed their average price target on BioMarin Pharmaceutical slightly, cutting fair value by about $0.30 to $55.36. They are factoring in a higher discount rate, modestly stronger long term growth and margins, and a slightly lower future P/E multiple following recent reassessments of the Voxzogo franchise and the planned Amicus acquisition.Narratiefupdate • Apr 15
BMRN: Fair Value View Balances Voxzogo Risks And Amicus Opportunity
The analyst fair value estimate for BioMarin Pharmaceutical has been trimmed from about $60 to roughly $55.66 as analysts factor in a higher discount rate, a lower future P/E multiple, and mixed expectations around Voxzogo and the Amicus acquisition. Analyst Commentary Recent research on BioMarin reflects a mixed but generally constructive stance, with several firms revising price targets while keeping positive ratings.Narratiefupdate • Apr 01
BMRN: Pending Amicus Deal Will Reshape Earnings Power Despite Treatment Franchise Risks
Analyst revisions point to a slightly lower blended fair value for BioMarin Pharmaceutical, trimming the price target by about $0.09 as analysts factor in mixed views on Voxzogo and the pending Amicus deal while keeping underlying growth, margin, and P/E assumptions broadly unchanged. Analyst Commentary Recent Street research reflects a split view on BioMarin, with most analysts still constructive on long term value creation while others focus on Voxzogo related risks and competitive pressures.Narratiefupdate • Mar 18
BMRN: Amicus Acquisition Is Expected To Reshape Future Earnings Power
Analysts have nudged their fair value estimate for BioMarin to $88.96 from $88.65, citing updates to revenue growth, profit margin and future P/E assumptions as they reassess Voxzogo risks, competitive pressure and the potential impact of the Amicus acquisition. Analyst Commentary Recent street research paints a mixed picture for BioMarin, with analysts recalibrating expectations around Voxzogo, the Amicus acquisition and the broader rare disease portfolio.
Narratiefupdate • Mar 03
BMRN: Rare Disease Portfolio Expansion And Amicus Acquisition Will Drive Repricing
Our BioMarin Pharmaceutical update trims the fair value estimate slightly to $120 from $122, as analysts weigh higher long term growth and margin assumptions against a higher discount rate and a lower future P/E multiple. Recent Street price target moves now cluster in the mid to high $90s, with outliers as low as $55 and as high as $105.Narratiefupdate • Feb 17
BMRN: Recent Coverage Shifts Will Support Higher Future Earnings Multiple
Analysts have trimmed their fair value estimate for BioMarin Pharmaceutical by roughly $2 to about $88.65. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions drawn from recent Street research.Narratiefupdate • Feb 03
BMRN: Shares Should Recover As Fresh Coverage Supports Higher Future Earnings Multiple
Analysts have lifted their price target for BioMarin Pharmaceutical by about US$1 to roughly US$91, citing updated assumptions around revenue growth, margins and a higher future P/E multiple, supported by recent positive Street research coverage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Street coverage as support for using a higher future P/E multiple, which feeds directly into a slightly higher fair value range around US$91.Narratiefupdate • Jan 20
BMRN: Reset Long Term Outlook Will Shape Risk Balance Going Forward
Analysts have reduced their price target on BioMarin Pharmaceutical to US$60 from US$67.39 as they factor in updated long term revenue scenarios, a higher discount rate, and slightly stronger margin assumptions following recent quarterly results and guidance changes. Analyst Commentary Recent Street research shows a cluster of price target cuts on BioMarin, generally following an "okay" Q3 print, a Q3 revenue miss in some areas, and updated long term guidance that now reflects a wider range of possible competitive and intellectual property outcomes.Narratiefupdate • Jan 06
BMRN: Shares Should Recover As 2027 Revenue Reset Clarifies Competition Risk
Analysts now see fair value for BioMarin Pharmaceutical at $89.74 per share, a small move up that reflects lower long term revenue growth assumptions, a slightly higher profit margin outlook, and modestly higher future P/E expectations following recent price target cuts tied to Voxzogo trends, revised 2027 revenue guidance, and potential competition. Analyst Commentary Recent Street research shows a wide range of views on BioMarin, with a clear focus on Voxzogo trends, updated 2027 revenue scenarios, and the impact of potential competition on execution and valuation.Narratiefupdate • Dec 16
BMRN: Shares Will Strengthen As 2025 Guidance Reset Supports Future Upside
Analysts have trimmed their average price target on BioMarin Pharmaceutical by roughly $1 to reflect a modest reset in long term revenue and margin expectations after Q3’s revenue miss, Voxzogo softness and greater acknowledgment of emerging competitive risks, even though they continue to view the shares as undervalued. Analyst Commentary Analyst reactions to BioMarin’s Q3 update reflect a more nuanced view of the company’s medium term growth profile, with reduced price targets but largely constructive ratings as investors recalibrate for competitive dynamics and updated long range guidance.Narratiefupdate • Dec 02
BMRN: Shares Will Strengthen As 2025 Guidance and Pipeline Progress Drive Upside
BioMarin Pharmaceutical's analyst price target has been reduced from $90.50 to $89.36. Analysts cite slightly lower growth and profit margin expectations, new competitive pressures, and revised long-term guidance as key drivers for the change.Narratiefupdate • Nov 18
BMRN: Shares Will Recover As Revenue Guidance Aligns With Market Expectations
Analysts have modestly reduced their price target for BioMarin Pharmaceutical, trimming it by $0.10 to $90.50. Recent updates reflect a more cautious outlook on revenue growth and profit margins in light of evolving competitive and regulatory expectations.Narratiefupdate • Nov 03
BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead
Analysts have lowered their average price target for BioMarin Pharmaceutical from about $94.80 to $90.60. This reflects a cautious view following revenue misses, reduced long-term guidance due to anticipated competition, and updated profit margin forecasts.Analyseartikel • Oct 30
Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts
Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its quarterly result to the...Narratiefupdate • Oct 20
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
BioMarin Pharmaceutical's analyst price target was revised slightly lower, decreasing from $95.16 to $94.80 per share as analysts weighed ongoing competitive risks to Voxzogo and modest changes to key financial assumptions. Analyst Commentary Recent analyst coverage of BioMarin Pharmaceutical reflects a mix of optimism and caution surrounding the company's future prospects, especially regarding its growth story, competitive landscape, and valuation relative to peers.Narratiefupdate • Oct 05
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Analysts have slightly lowered their price target for BioMarin Pharmaceutical to $95.16. This adjustment reflects carefully balanced views on future revenue growth, competitive risks affecting key drugs, and the company's ongoing potential for pipeline advancement.Analyseartikel • Aug 06
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
NasdaqGS:BMRN 1 Year Share Price vs Fair Value Explore BioMarin Pharmaceutical's Fair Values from the Community and...Analyseartikel • Jul 22
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc.'s ( NASDAQ:BMRN ) price-to-earnings (or "P/E") ratio of 20.7x might make it look like a...Seeking Alpha • Jan 23
BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
Summary BioMarin's stock has dropped over 26% since July 2024, raising questions about whether it's a bargain or a falling knife. Key issues include valuation, stock volatility, an underwhelming investor's day, and competition with their drug VOXZOGO. The sharp decline in share price invites a reassessment of BioMarin's current investment prospects. Investors need to weigh the potential for recovery against the risks of further declines. Read the full article on Seeking AlphaSeeking Alpha • Nov 21
Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Summary Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth. Elliott Investment Management is invested in the company and may be attempting to position the business for a sale. Management's forecasts may be over-ambitious, and Wall Street's current valuation of the business too low. The prospect of a sale tips the balance in favour of a "Buy" recommendation. Read the full article on Seeking AlphaSeeking Alpha • Aug 21
BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Summary BioMarin Pharmaceutical Inc. sales of Voxzogo had increased by 62% to $184 million in Q2 of 2024, compared to the same period in 2023. Potential to eventually expand the use of Voxzogo towards other indications like hypochondroplasia and idiopathic short stature. Data from the phase 1/2 study, using BMN351 for the treatment of patients with DMD amenable to exon 51 skipping, expected by the end of 2024. The global Duchenne Muscular Dystrophy Treatment market size is expected to reach $8.19 billion by 2029; It is said that about 13% of DMD patients are amenable to exon 51 skipping. Read the full article on Seeking AlphaSeeking Alpha • Jul 24
BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Summary BioMarin's shares have enjoyed three strong, albeit brief, updrafts in recent years. It plans to reveal its latest strategies for developing its rich portfolio of approved drugs at its 09/2024 investor's day. With ample liquidity and positive earnings BioMarin's financial profile is steady. Read the full article on Seeking AlphaSeeking Alpha • May 15
BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
Summary BioMarin's 1Q24 revenue was $649 million, with a 9% YoY increase, but uncertainty around the commercial prospects of Roctavian has dampened optimism. The company's core drug portfolio performed as expected, with some drugs exceeding consensus expectations and others falling short. Voxzogo remains a strong revenue driver, with sales of $153 million in 1Q24, and plans to expand into new indications, potentially significantly expanding the addressable market. I maintain my bullish view on BMRN stock, but it has become less bullish. My new fair price for BMRN is $112. Read the full article on Seeking AlphaOpbrengsten en kosten
Opbrengsten en kosten
Hoe BioMarin Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 3,242 | 269 | 1,075 | 0 |
| 31 Dec 25 | 3,221 | 349 | 1,031 | 0 |
| 30 Sep 25 | 3,094 | 520 | 878 | 0 |
| 30 Jun 25 | 3,064 | 657 | 863 | 0 |
| 31 Mar 25 | 2,950 | 524 | 989 | 0 |
| 31 Dec 24 | 2,854 | 427 | 1,009 | 0 |
| 30 Sep 24 | 2,753 | 322 | 1,002 | 0 |
| 30 Jun 24 | 2,588 | 257 | 964 | 0 |
| 31 Mar 24 | 2,472 | 205 | 907 | 0 |
| 31 Dec 23 | 2,419 | 168 | 892 | 0 |
| 30 Sep 23 | 2,311 | 147 | 856 | 0 |
| 30 Jun 23 | 2,235 | 100 | 857 | 0 |
| 31 Mar 23 | 2,173 | 72 | 847 | 0 |
| 31 Dec 22 | 2,096 | 142 | 823 | 0 |
| 30 Sep 22 | 2,008 | 84 | 826 | 0 |
| 30 Jun 22 | 1,912 | 54 | 792 | 0 |
| 31 Mar 22 | 1,880 | 39 | 780 | 0 |
| 31 Dec 21 | 1,846 | -64 | 759 | 0 |
| 30 Sep 21 | 1,849 | 16 | 737 | 0 |
| 30 Jun 21 | 1,917 | 837 | 733 | 0 |
| 31 Mar 21 | 1,844 | 795 | 725 | 0 |
| 31 Dec 20 | 1,860 | 854 | 738 | 0 |
| 30 Sep 20 | 1,863 | 852 | 730 | 0 |
| 30 Jun 20 | 1,847 | 122 | 721 | 0 |
| 31 Mar 20 | 1,805 | 114 | 706 | 0 |
| 31 Dec 19 | 1,704 | -24 | 681 | 0 |
| 30 Sep 19 | 1,603 | -43 | 657 | 0 |
| 30 Jun 19 | 1,533 | -110 | 636 | 0 |
| 31 Mar 19 | 1,519 | -90 | 628 | 0 |
| 31 Dec 18 | 1,491 | -77 | 604 | 0 |
| 30 Sep 18 | 1,496 | -125 | 600 | 0 |
| 30 Jun 18 | 1,439 | -125 | 582 | 0 |
| 31 Mar 18 | 1,383 | -145 | 573 | 0 |
| 31 Dec 17 | 1,314 | -117 | 554 | 0 |
| 30 Sep 17 | 1,255 | -156 | 537 | 0 |
| 30 Jun 17 | 1,201 | -181 | 525 | 0 |
| 31 Mar 17 | 1,184 | -563 | 491 | 0 |
| 31 Dec 16 | 1,117 | -630 | 477 | 0 |
| 30 Sep 16 | 1,045 | -471 | 441 | 0 |
| 30 Jun 16 | 974 | -524 | 416 | 0 |
| 31 Mar 16 | 924 | -187 | 408 | 0 |
| 31 Dec 15 | 890 | -172 | 402 | 0 |
| 30 Sep 15 | 892 | -310 | 385 | 0 |
| 30 Jun 15 | 859 | -212 | 366 | 0 |
Kwaliteitswinsten: BMRN heeft een grote eenmalige verlies van $249.6M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 31st March, 2026.
Groeiende winstmarge: De huidige netto winstmarges (8.3%) BMRN } zijn lager dan vorig jaar (17.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van BMRN is de afgelopen 5 jaar met 10.5% per jaar gegroeid.
Versnelling van de groei: De winstgroei BMRN is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.
Winst versus industrie: BMRN had het afgelopen jaar een negatieve winstgroei ( -48.7% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Biotechs ( 43% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 4.3% ) van BMRN wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 08:54 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
BioMarin Pharmaceutical Inc. wordt gevolgd door 48 analisten. 25 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jack Allen | Baird |
| Ying Huang | Barclays |
| Eliana Merle | Barclays |